Foundry Healthcare Sales Discipline Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1ROIV | ROIVANT SCIENCES LTD | Healthcare | $24.82B | 13.12% |
2MRNA | MODERNA INC | Healthcare | $24.53B | 12.97% |
3BAX | BAXTER INTERNATIONAL INC | Healthcare | $11.68B | 6.17% |
4KYMR | KYMERA THERAPEUTICS INC | Healthcare | $9.52B | 5.03% |
5PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $9.06B | 4.79% |
6PRAX | PRAXIS PRECISION MEDICINES INC | Healthcare | $8.77B | 4.63% |
7XENE | XENON PHARMACEUTICALS INC | Healthcare | $6.60B | 3.49% |
8PTCT | PTC THERAPEUTICS INC | Healthcare | $6.52B | 3.45% |
9TFX | TELEFLEX INC | Healthcare | $5.96B | 3.15% |
10DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.77B | 3.05% |
11CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.61B | 2.44% |
12ICUI | ICU MEDICAL INC | Healthcare | $3.94B | 2.08% |
13ALMS | ALUMIS INC | Healthcare | $3.65B | 1.93% |
14OGN | ORGANON & CO | Healthcare | $3.55B | 1.88% |
15HAE | HAEMONETICS CORP | Healthcare | $3.54B | 1.87% |
16CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.77B | 1.47% |
17IMNM | IMMUNOME INC | Healthcare | $2.53B | 1.34% |
18NRIX | NURIX THERAPEUTICS INC | Healthcare | $2.40B | 1.27% |
19PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.36B | 1.25% |
20NKTR | NEKTAR THERAPEUTICS | Healthcare | $2.31B | 1.22% |
21NEOG | NEOGEN CORP | Healthcare | $2.24B | 1.18% |
22AGL | AGILON HEALTH INC | Healthcare | $2.17B | 1.15% |
23MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.15B | 1.13% |
24GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $2.07B | 1.10% |
25OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.96B | 1.04% |
26MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.99% |
27SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.96% |
28STOK | STOKE THERAPEUTICS INC | Healthcare | $1.81B | 0.96% |
29ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.93% |
30TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 0.90% |
31PSNL | PERSONALIS INC | Healthcare | $1.61B | 0.85% |
32PRGO | PERRIGO CO PLC | Healthcare | $1.48B | 0.78% |
33NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.71% |
34XNCR | XENCOR INC | Healthcare | $1.30B | 0.68% |
35ABSI | ABSCI CORP | Healthcare | $1.29B | 0.68% |
36AZTA | AZENTA INC | Healthcare | $1.21B | 0.64% |
37QDEL | QUIDELORTHO CORP | Healthcare | $1.19B | 0.63% |
38CAPR | CAPRICOR THERAPEUTICS INC | Healthcare | $1.13B | 0.60% |
39WVE | WAVE LIFE SCIENCES LTD | Healthcare | $1.12B | 0.59% |
40EYPT | EYEPOINT INC | Healthcare | $1.12B | 0.59% |
41AVTX | AVALO THERAPEUTICS INC | Healthcare | $1.02B | 0.54% |
42AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $871M | 0.46% |
43ACRS | ACLARIS THERAPEUTICS INC | Healthcare | $793M | 0.42% |
44CSTL | CASTLE BIOSCIENCES INC | Healthcare | $733M | 0.39% |
45EVH | EVOLENT HEALTH INC | Healthcare | $654M | 0.35% |
46STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.31% |
47ARVN | ARVINAS INC | Healthcare | $517M | 0.27% |
48DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $517M | 0.27% |
49RGNX | REGENXBIO INC | Healthcare | $511M | 0.27% |
50NRC | NRC HEALTH | Healthcare | $491M | 0.26% |
51PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.24% |
52PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.23% |
53CCRN | CROSS COUNTRY HEALTHCARE INC | Healthcare | $428M | 0.23% |
54EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.21% |
55LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.16% |
56MASS | 908 DEVICES INC | Healthcare | $278M | 0.15% |
57TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.14% |
58SRZN | SURROZEN INC | Healthcare | $255M | 0.13% |
59RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $243M | 0.13% |
60RXST | RXSIGHT INC | Healthcare | $230M | 0.12% |
61SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.12% |
62UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $222M | 0.12% |
63KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.11% |
64DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.11% |
65AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.11% |
66KRRO | KORRO BIO INC | Healthcare | $177M | 0.09% |
67ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.09% |
68JYNT | JOINT CORP | Healthcare | $127M | 0.07% |
69SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $120M | 0.06% |
70ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.04% |
71CLNN | CLENE INC | Healthcare | $76M | 0.04% |
72SCLX | SCILEX HOLDING CO | Healthcare | $72M | 0.04% |
73AGPU | AXE COMPUTE INC | Healthcare | $72M | 0.04% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $189.15B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 80% toward Large, 41% toward Growth. +19% unclassified (15 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 73 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 73 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Publication date unknown. We don’t have a source year for this signal, so we can’t split its record into before and since publication. That’s a gap in our reference data — not a statement about how the factor performed.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 74.2% | 7.6% |
| 3 yearsp.a. | 16.2% | 1.6% |
| 5 yearsp.a. | 6.1% | 6.4% |
| 10 yearsp.a. | 7.3% | 1.7% |
| Since inceptionp.a. | 8.0% | 2.1% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 39.3% | 26.8% |
| 2025 | 29.5% | -13.1% |
| 2024 | -9.0% | -5.5% |
| 2023 | -4.9% | 11.8% |
| 2022 | -0.8% | 17.0% |
| 2021 | -0.8% | -7.9% |
| 2020 | 39.9% | 27.5% |
| 2019 | 9.8% | -19.2% |
| 2018 | -12.4% | 6.5% |
| 2017 | 6.4% | -18.3% |
| 2016 | 1.4% | 11.6% |
| 2015 | 10.8% | -5.4% |
| 2014 | 18.7% | -10.3% |
| 2013 | 34.2% | -17.1% |
| 2012 | 31.3% | 15.4% |
| 2011 | 7.5% | 4.0% |
| 2010 | 17.0% | 11.3% |
| 2009 | 18.8% | -12.6% |
| 2008 | -16.2% | 13.6% |
| 2007 | -3.8% | -21.7% |
| 2006 | 19.4% | 21.9% |
| 2005 | 0.8% | -17.8% |
| 2004 | -4.6% | 3.4% |
| 2003 | 17.3% | -11.3% |
| 2002 | -38.4% | 13.8% |
| 2001 | -14.0% | 16.1% |
| 2000 | 77.5% | 57.2% |
| 1999 | 6.5% | -0.1% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare Sales Discipline Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Sales Discipline signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.